The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 801–900 of 988
Choi, H., Lee, J., Oh, H., Kim, M., Kho, B., Park, C., Oh, I., & Kim, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13957 · Cited by 2
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Gómez, R., Lombana, M., Vargas, C., Duarte, R., Lobatón, J. F., Yepes, A., et al. (2018) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.364 · Cited by 2
Zhou, J., Bai, J., Yue, Y., Chen, X., Lange, T., You, D., & Zhao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.757456 · Cited by 3
Rui, M., Wang, Z., Fei, Z., Wu, Y., Wang, Y., Sun, L., Shang, Y., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.862640 · Cited by 2
Lampaki, S., Mountzios, G., Georgoulias, V., Rapti, A., Xanthakis, I., Baka, S., Mavroudis, D., Samantas, E., Athanasiadis, E., Zagouri, F., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0386 · Cited by 2
Predictive Tumor Biomarkers for EGFR Inhibitors
Kim, L., Liu, G., & Tsao, M. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch28 · Cited by 2
Being molecular in the molecular age
Raghupathy, R., & Mok, T. S. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw002 · Cited by 2
First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
Jeong, B., & Um, S. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.12.30 · Cited by 2
Challenges of dispensing costly tablets with short shelf-life
de Lemos, M. L., Mathers, B., Badry, N., Hamata, L., & Lo, K. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218777815 · Cited by 2
Sperduto, P. W., & Lou, E. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab054 · Cited by 2
Thilagavathy, G., Durairaj, R., Shobana, C., & Usharani, B. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is5.2391 · Cited by 1
Hepatotoxicity of Anti-cancer Drugs
Bayram, D., & Uçar, G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_344 · Cited by 1
Chen, Y., Liu, Q.-P., Yang, S.-J., Ding, J., Lu, X.-Y., & Xie, H. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01855-0 · Cited by 1
Self-citationTokunaga, T., Tomioka, Y., Harada-Takeda, A., Ishihara, Y., Nagata, A., Kato, M., Suetsugu, T., Mizuno, K., Aoki, M., Ueda, K., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146412 · Cited by 1
[TKI Resistance for T790M Mutation].
Wang, H., Guo, R., & Zhang, L. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.04.10 · Cited by 1
Afatinib for the treatment of non-small cell lung cancer
Biello, F., Maggioni, C., Rijavec, E., Genova, C., Barletta, G., Gualco, E., Truini, A., Coco, S., Bello, M. G. D., Vanni, I., et al. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1092379 · Cited by 1
Grève, J. D., Decoster, L., van Brummelen, D., Geers, C., & Schallier, D. C. C. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.06.04 · Cited by 1
Kim, E. Y., Kim, Y.-H., Ban, H., Oh, I., Kwon, Y. S., Kim, K., Kim, Y., Lim, S., & Kim, Y. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.74.3.129 · Cited by 1
Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?
González, G., Díaz-Miqueli, A., Crombet, T., Raez, L. E., & Lage, A. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.48a010 · Cited by 1
Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC
Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer
Peters, S., & Smit, E. F. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71027-7 · Cited by 1
Manzo, A., Corte, C. M. D., Festino, L., Fasano, M., Ciardiello, F., & Morgillo, F. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.73 · Cited by 1
Serra-Solé, Ò., Pujol-Riqué, M., & Cuartero, L. C. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.20 · Cited by 1
Fricke, U., & Schwabe, U. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_2 · Cited by 1
Reversion of erlotinib-acquired resistance twice by chemotherapy
Teng, F., Zhang, J., Meng, X., & Yu, J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27221 · Cited by 1
Maemondo, M. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.1314 · Cited by 1
Patel, J. N., & Villadolid, J. J. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0754-3.ch003 · Cited by 1
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer
Noble, J., & Ellis, P. (2013) · Cited by 1
Recent advances in the management of advanced non–small-cell lung cancer
Aggarwal, C., & Langer, C. J. (2013) · Community Oncology · doi:10.12788/j.cmonc.0005 · Cited by 1
Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC
Melosky, B., Sheffield, B. S., Tsou, M.-H., Gagne, S., Ionescu, D. N., & Yang, J. C. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.02.005 · Cited by 1
Self-citationPlasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge
Nakamura, T., Watanabe, N., Sato, A., Komiya, K., Umeguchi, H., Hosomi, T., Hirai, M., Sueoka, E., Kimura, S. H., & Sueoka‐Aragane, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.6085 · Cited by 1
Kızılgöz, D., Kabalak, P. A., Cengiz, T. İ., Yılmaz, Ü., Özaydın, H. E., Ekinci, Ö., Akyürek, N., & Kavurgacı, S. (2017) · Respiratory Case Reports · doi:10.5505/respircase.2017.48403 · Cited by 1
Youngren-Ortiz, S. R., & Chougule, M. B. (2017) · Europe PMC (PubMed Central) · Cited by 1
Performance of Japanese patients in registrational studies
Goto, Y., Arakawa, S., Shirasawa, M., Higashiyama, R. I., Baba, K., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., Yoshida, T., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab171 · Cited by 1
Kuzmina, V. A., Лактионов, К. К., Реутова, Е. В., Ardzinba, M. A., & Denisova, E. S. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-22-154-159 · Cited by 1
Immune killer cells treatment for previously treated stage IV NSCLC patients
Tseng, Y.-H., Ho, C.-L., Chian, C., Chiang, C., Chao, H., Tsai, C., Perng, W., Hsiao, C., Chuang, M.-H., Ko, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-69587-x · Cited by 1
Self-citationZhou, Y., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.06.04 · Cited by 1
Self-citationNelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.63 · Cited by 1
Frith, A. E., & Baggstrom, M. Q. (2014) · Current Geriatrics Reports · doi:10.1007/s13670-014-0092-7 · Cited by 1
Afatinib: rationale for use in non-small-cell lung cancer based on clinical trial data
Espinosa, A. V., & Horn, L. (2013) · Clinical Investigation · doi:10.4155/cli.13.120 · Cited by 1
Safety and efficacy of targeted agents monotherapy in advanced NSCLC
Zhang, Q., & Wu, Y.-L. L. C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1101340 · Cited by 1
Bhateja, P., & Sharma, N. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.09.45 · Cited by 1
Sakaeva, D. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-6-38-50 · Cited by 1
Noor, Z. S., & Goldman, J. W. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_1 · Cited by 1
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00025-1 · Cited by 1
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 1
Song, S.-Y., Ha, S., Park, J., Park, S. J., Shin, S. H., Oak, C., Choi, J. Y., Yoon, S. W., Kim, J.-A., Yoon, S. H., et al. (2020) · Medicine · doi:10.1097/md.0000000000023455 · Cited by 1
Self-citationDermatological Toxicities of Targeted Therapy
Pansare, R., Nagasaka, M., & Sukari, A. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00015-x · Cited by 1
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
Wang, W., Li, J., Ma, S., Li, H., Gao, Z., & Qu, M. (2021) · Journal of Clinical Research in Oncology · doi:10.33309/2639-8230.040101 · Cited by 1
Patel, J. N., & Villadolid, J. J. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch008 · Cited by 1
Interview: Changing advanced lung cancer into chronic disease
Yang, J. C. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.68 · Cited by 1
Self-citationJeong, B., & Um, S. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.37 · Cited by 1
(2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220985357 · Cited by 1
Terai, H., Hamamoto, J., Emoto, K., Masuda, T., Manabe, T., Kuronuma, S., Kobayashi, K., Masuzawa, K., Ikemura, S., Nakayama, S., et al. (2023) · doi:10.1158/1541-7786.c.6545117.v1 · Cited by 1
Pharmacogenetics and Antineoplastic Therapies
Patel, J. N., Walko, C. M., & Innocenti, F. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-15344-5_10
[Advances of molecular subtype and targeted therapy of lung cancer].
Shao, L., Song, Z., Zhang, Y., & Su, D. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.09.07
An Improved Procedure for the Preparation of Poziotinib
Cai, Z., Ma, W., & Hou, X. (2015) · International Conference on Mechatronics, Electronic, Industrial and Control Engineering (MEIC) · doi:10.2991/meic-15.2015.176
Agents in the preclinical development stage for non-small cell lung cancer
Sacco, P. C., Sgambato, A., Casaluce, F., Maione, P., Rossi, A., Palazzolo, G., Napolitano, A., & Gridelli, C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1092875
Strategy on Patients with EGFR Mutation
Früh, M., Zhou, Q. H., Leung, L. K. S., & Mok, T. S. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_9
INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
Saraiva, S., Morgado, S., & Morgado, M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v5i3.44
Téllez-Bernal, E., Aguilar-Jiménez, C., Adel-Álvarez, L. A., Espinoza, I. R. G., & López, A. M. (2014) · Gaceta Mexicana de Oncología
Les mutations de HER2 dans les cancers bronchiques : caractéristiques et perspectives thérapeutiques
Mazières, J., & Milia, J. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70318-x
Targeted Therapy For Lung Cancer: Reviewing the Cost and Its Effect on Treatment Decisions
Lim, C. H., Sergi, M., & Leighl, N. B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.36
Non-small-cell lung cancer: promising advances in treatment
Quintyne, K. I., Walsh, L., & Coate, L. E. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70008-0
Afatinib in Advanced Non-Small-Cell Lung Cancer
Maïo, M. D., Gridelli, C., Grossi, F., Novello, S., & de Marinis, F. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.49
New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer
Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63
Pécuchet, N., Bigot, F., Henni, M., & Fabre, E. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.12.005 · Cited by 1
Reck, M., Reinmuth, N., & Heigener, D. F. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.29
Thérapies ciblées : quel traitement pour quel patient ?
Berghmans, T. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70601-9
Pharmacology and Clinical Development of New Molecularly Targeted Agents
Giovannetti, E., & Galvani, E. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_3
Managing Non-Small-Cell Lung Cancer with Acquired Resistance to EGF Receptor and ALK Inhibitors
Lee, S. M., & King, J. P. (2013) · Lung Cancer Management · doi:10.2217/lmt.12.56
NOVeL treatMeNts tO OVercOMe tKI resIstaNce
Sacher, A. G. (2014)
JSM Clinical Oncology and Research
(2024) · JSM Clinical Oncology and Research · doi:10.47739/2373938x/oncology
Blakely, C. M., & Bivona, T. G. (2012)
Overcoming EGFR-TKI Resistance
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_4
ZEPHYR: failure of a "spring wind" in lung cancer.
Morabito, A. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.10.10
Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?
Ou, S. I. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.10
Cancers bronchiques non à petites cellules mutés ou réarrangés : de la premiere á la énième ligne
Raimbourg, J., & Douillard, J. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30032-5
Therapeutic implication of molecular profiling in patients with non – small cell lung cancer
Jakopović, M., Ježek, S. S., Chalfe, N., Redžepi, G., Makek, M. J., Čučević, B., Korte, D. M., Rokotov, D. S., & Samaržija, M. (2012) · Hrčak Portal of scientific journals of Croatia (University Computing Centre)
10.5937/mckg48-2741 = New pharmacological strategies in the treatment of non-small cell lung cancer
Kostić, I., Vrndic, O. B., Jeftic, I. D., & Ćupurdija, V. (2014) · Medicinski casopis · doi:10.5937/mckg48-2741
Mattsson, J. S. M. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Evidencia de afatinib en pacientes que progresan a un tratamiento de primera línea
Artal, A., Pelegrín, J. G., & Alejandro, M. Á. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30259-7
Zheng, J., Bai, X., Hong, C., Gao, H., & Li, X. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1220830
Signal Transduction Inhibitors of the HER Family
Brzezniak, C. E., Carter, C. A., Thomas, A., & Giaccone, G. (2013) · CRC Press eBooks · doi:10.1201/b15944-3
Fenton, M. J. (2015) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2015.11.02.128
Covalent Kinase Inhibitors for Cancer
Owens, T. D., & Lou, Y. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12399-6
Targeting epidermal growth factor receptor: An important strategy in oncology
Kharatmol, M. G., & Jagdale, D. M. (2017) · International Journal of Pharma and Bio Sciences · doi:10.22376/ijpbs.2017.8.1.p174-182
Non-genetic resistant mechanism to EGFR tyrosine kinase inhibitory therapy
Tan, S. Z. (2015) · TSpace (University of Toronto)
Mechanisms of IKBKE Activation in Cancer
Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)
Santoni, N., Melo, T., Aguirre, A. R., Veiga, D., & Souza, C. (2017) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v9.n1.p73-82
Clay, T. D. (2017) · Minerva Access (University of Melbourne)
Gauvain, C., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30057-5
Карабина, Е. В., Lubchenko, L. N., & Давыдов, М. М. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-14-46-55
Liu, M., Wang, Z., Zhou, H.-W., Zhou, M., Gu, Y., Yao, Y., & Sun, J. (2017) · Biomedical Research-tokyo
Nucleophilic Aroylation on Fluoroquinazolines Catalyzed by N-Heterocyclic Carbenes
Suzuki, Y., Tachikawa, M., & Nakagawa, M. (2018) · Heterocycles · doi:10.3987/com-18-13880
Delineating the biology of Anaplastic Lymphoma Kinase (ALK) and its resistance to crizotinib
Alshareef, A. (2017) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3nz81414
EGFR inhibitors and their use in the treatment of metastatic disease
Gridelli, C., & Rossi, A. (2012) · doi:10.2217/ebo.12.29
Ikeda, M., Ochibe, T., & Tohkin, M. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479018791135
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
